Cannabinoid-focused Lexaria Bioscience Corp. (CNSX:LXX) (OTCMKTS:LXRP) has applied for a Health Canada license to operate a research and development lab at the new headquarters the company is building in Kelowna, British Columbia.
Lexaria said in a press release Monday that the lab will enhance its ability to formulate for analytical purposes various products that may contain cannabinoids or other controlled substances.
READ: Lexaria Bioscience creates four new subsidiaries
The company added that it expects to work on cannabinoid-related formulations as soon as the lab receives its research license. Experimental work on nicotine formulations, non-steroidal anti-inflammatory drugs, vitamins and other bioactive compounds will begin soon after completion of lab construction. The company expects to occupy the new headquarters and lab by the end of January 2019.
Separately, the company said it has appointed Dr Ed Ergenzinger as chief legal officer and senior vice president of innovation. Ergenzinger is a US-licensed patent attorney who also holds a doctorate in neuroscience with concentrations in pharmacology and physiology.
Shares of Lexaria slipped C$0.21 to C$1.35 in Tuesday’s Canadian trading. They were down US$0.16 to US$1.03 on the OTC market.
Contact Dennis Fitzgerald at dennis@proactiveinvestors.com